Chang, C.-J.; Hsu, W.-F.; Jeng, L.-B.; Lai, H.-C.; Hsu, S.-C.; Chen, T.-H.; Wang, H.-W.; Peng, C.-Y.
Adjuvant Sorafenib for Postoperative Patients with Hepatocellular Carcinoma and Macrovascular Invasion. Curr. Oncol. 2023, 30, 10134-10141.
https://doi.org/10.3390/curroncol30120737
AMA Style
Chang C-J, Hsu W-F, Jeng L-B, Lai H-C, Hsu S-C, Chen T-H, Wang H-W, Peng C-Y.
Adjuvant Sorafenib for Postoperative Patients with Hepatocellular Carcinoma and Macrovascular Invasion. Current Oncology. 2023; 30(12):10134-10141.
https://doi.org/10.3390/curroncol30120737
Chicago/Turabian Style
Chang, Che-Jui, Wei-Fan Hsu, Long-Bin Jeng, Hsueh-Chou Lai, Shih-Chao Hsu, Te-Hung Chen, Hung-Wei Wang, and Cheng-Yuan Peng.
2023. "Adjuvant Sorafenib for Postoperative Patients with Hepatocellular Carcinoma and Macrovascular Invasion" Current Oncology 30, no. 12: 10134-10141.
https://doi.org/10.3390/curroncol30120737
APA Style
Chang, C.-J., Hsu, W.-F., Jeng, L.-B., Lai, H.-C., Hsu, S.-C., Chen, T.-H., Wang, H.-W., & Peng, C.-Y.
(2023). Adjuvant Sorafenib for Postoperative Patients with Hepatocellular Carcinoma and Macrovascular Invasion. Current Oncology, 30(12), 10134-10141.
https://doi.org/10.3390/curroncol30120737
